Skip to main content

Peer Review reports

From: Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

Original Submission
20 Jul 2020 Submitted Original manuscript
23 Jul 2020 Author responded Author comments - Jiri Minarik
Resubmission - Version 2
23 Jul 2020 Submitted Manuscript version 2
17 Nov 2020 Author responded Author comments - Jiri Minarik
9 Sep 2020 Reviewed Reviewer Report
21 Oct 2020 Reviewed Reviewer Report
Resubmission - Version 3
17 Nov 2020 Submitted Manuscript version 3
11 Dec 2020 Author responded Author comments - Jiri Minarik
3 Dec 2020 Reviewed Reviewer Report
24 Nov 2020 Reviewed Reviewer Report
Resubmission - Version 4
11 Dec 2020 Submitted Manuscript version 4
Publishing
14 Dec 2020 Editorially accepted
15 Jan 2021 Article published 10.1186/s12885-020-07732-1

You can find further information about peer review here.

Back to article page
\